Quintiles has signed a deal with a Roche diagnostics subsidiary to offer cancer screenings in China, looking to capitalize on the growing market for clinical trials in the country.
Ventana and Quintiles are partnering up to provide companion diagnostic testing services in China for early clinical trials. China is among a few countries that requires patient samples used in clinical trials to be tested domestically for inclusion in the country's approval process.
Quintiles hit the $1 billion revenue mark for a third straight quarter, dialing up its full-year guidance as it expands its share of the global outsourcing market.
Basilea Pharmaceutica ran into an FDA roadblock in its efforts to commercialize a new antibiotic, but the Swiss drug developer already has a green light in Europe, and it's tapping Quintiles' global marketing expertise to launch the treatment on its home continent.
Quintiles has wrapped up its acquisition of healthcare analytics provider Encore, part of the CRO's push to grow its post-market services.
Quintiles believes in better drug sales through data analytics, signing a deal with a marketing-optimization company to pool resources and figure out how to better reach physicians on behalf of its commercialization clients.
Quintiles, the world's largest CRO, is lending its Big Data heft to the American Physical Therapy Association, agreeing to help create a registry of patient outcomes data to inform future treatment.
Quintiles, the world's largest CRO, is further expanding its outside-the-clinic business, agreeing to buy healthcare analytics outfit Encore Health Resources to beef up its access to real-world patient data.
Quintiles, the world's largest CRO, hit the $1 billion service revenue threshold for the second time last quarter, piling up new business wins with eyes on its biggest year ever.
Biogen Idec has struck up a far-reaching agreement with CRO giant Quintiles, tapping the contractor to help design, plan and run its Phase II-IV studies.